Semenogelin, the main protein of semen coagulum, inhibits human sperm capacitation by interfering with the superoxide anion generated during this process.
Semenogelin (Sg), the major protein of the human semen coagulum, is present at high concentrations in seminal vesicle secretions. It is degraded by the prostate-specific antigen (PSA) to generate peptides of various biological activities that were found on and inside spermatozoa. Our aim was to determine the effect of Sg on capacitation, which is the series of transformations that spermatozoa must undergo to become fertile. At concentrations of 0.1 to 1.0 mg/mL (600- to 20-fold lower than those of semen), Sg did not affect sperm motility (%) but completely prevented capacitation induced by fetal cord serum ultrafiltrate; a partial inhibition of capacitation was noted with 0.03 mg Sg/mL. There was also a dose-dependent decrease in the tyrosine phosphorylation of fibrous sheath proteins and in the O2-.-related chemiluminescence. Ribonuclease (RNase), which has as high an isoelectric point (pI = 9.7) as Sg (pI = 9.5), also prevented sperm capacitation and O2-.-related chemiluminescence but to a lower extent, suggesting that one mechanism of Sg action on spermatozoa could be related to its positive charge at physiological pH. Sg at 1, but not 0.3 or 0.1 mg/mL, scavenged the O2-. generated by the mix of xanthine + xanthine oxidase and modified the kinetics of the reaction; RNase did not have such effects. Therefore, Sg is a potential scavenger for O2-. but probably also affects the sperm oxidase. Spermatozoa rapidly processed Sg; a high proportion of Sg was degraded after 15 minutes of incubation. The resulting polypeptide patterns were reminiscent of those obtained with PSA as a proteolytic enzyme. These data suggest that Sg, its degradation products, or both may be natural regulators of sperm capacitation and could prevent this process from occurring prematurely. One mechanism by which Sg acts could involve an interference with the O2-. that is normally generated during this process.
de Lamirande
E
E
Urology Research Laboratory, Royal Victoria Hospital and McGill University, Montréal, Québec, Canada. edelamirande@hotmail.com
Yoshida
K
K
Yoshiike
T M
TM
Iwamoto
T
T
Gagnon
C
C
D006801:Humans; D008297:Male; D010766:Phosphorylation; D017430:Prostate-Specific Antigen / Q000378:metabolism; D012260:Ribonucleases / Q000378:metabolism; D029607:Seminal Vesicle Secretory Proteins / Q000378:metabolism / Q000493:pharmacokinetics*; D013075:Sperm Capacitation / Q000187:drug effects* / Q000502:physiology; D013094:Spermatozoa / Q000378:metabolism*; D013481:Superoxides / Q000378:metabolism*; D014443:Tyrosine / Q000378:metabolism; D019820:Xanthine / Q000494:pharmacology; D014969:Xanthine Oxidase / Q000494:pharmacology
D029607:Seminal Vesicle Secretory Proteins; C424482:seminal vesicle-specific antigen; D013481:Superoxides; D019820:Xanthine; D014443:Tyrosine; D014969:Xanthine Oxidase; D012260:Ribonucleases; D017430:Prostate-Specific Antigen